MedTrace Logo

Arginine as an Adjuvant Treatment Against Tuberculosis

NCT00857402 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2009-03-06

No results posted yet for this study

Summary

The purpose of this study was to investigate if adjuvant treatment with arginine (the substrate for nitric oxide production) rich food supplements could improve clinical outcome in patients with smear positive tuberculosis by affecting nitric oxide production.

Conditions

Interventions

DIETARY_SUPPLEMENT

Peanuts

30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.

DIETARY_SUPPLEMENT

Daboqolo

30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.

Sponsors & Collaborators

  • University of Gondar

    collaborator OTHER

  • Kalmar County Hospital

    collaborator OTHER

  • Linkoeping University

    lead OTHER_GOV

Principal Investigators

  • Thomas Schön, MD PhD · Linkoeping University

  • Sven Britton, Professor · Karolinska Institutet

  • Tommy Sundqvist, Professor · Linkoeping University, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • Ethiopia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857402 on ClinicalTrials.gov